Evolution of Pulmonary Function in a Cohort of Interstitial Lung Disease Patients Positive to Antisynthetase Antibodies (ASAB).

CONCLUSION: Improvement of pulmonary function was observed in 67% of the patients, improvement was observed in all ASAB groups and occurred within the 6 months after initiating medical treatment. PMID: 31203227 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31203227?dopt=Abstract

Source: J Rheumatol - June 14, 2019 Category: Rheumatology Authors: González-Pérez MI, Mejía-Hurtado JG, Pérez-Román DI, Buendía-Roldán I, Mejía M, Falfán-Valencia R, Toledo HNM, Rojas-Serrano J Tags: J Rheumatol Source Type: research

More News: Interstitial Lung Disease | Rheumatology